Bora Pharmaceuticals Co., Ltd. (TPE:6472)
Taiwan · Delayed Price · Currency is TWD 419.50
-24.00 (-5.41%)
Jun 25, 2026, 1:30 PM CST
Bora Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Bora Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $700.86. The average 1-year stock price forecast is 67.07% higher than the current stock price, while the lowest is $430.00 (+2.50%) and the highest is $1,060 (+152.68%).
Price Target: $700.86 (+67.07%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bora Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Financial Forecast
Revenue This Year
22.55B
from 19.01B
Increased by 18.59%
Revenue Next Year
32.51B
from 22.55B
Increased by 44.18%
EPS This Year
33.73
from 23.24
Increased by 45.13%
EPS Next Year
51.56
from 33.73
Increased by 52.87%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is TWD.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 28.8B | |
| Avg | 22.5B | |
| Low | 19.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 51.7% | |
| Avg | 18.6% | |
| Low | 4.7% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 49.54 | |
| Avg | 33.73 | |
| Low | 16.63 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | 113.2% | |
| Avg | 45.1% | |
| Low | -28.4% |